Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 4,672 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Respiratory Therapy Clear all

Conditions: Covid19, SARS-CoV Infection, ARDS, ARDS, Human
Interventions: Instilled T3, Placebo Therapy; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Non-Small Cell Lung Cancer
Interventions: MEDI4736; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 28
States / cities: Goodyear, Arizona • Santa Rosa, California • New Haven, Connecticut + 22 more

Conditions: Non Small Cell Lung Cancer
Interventions: Pre-Treatment Biopsy, On-Treatment Biopsy, Biopsy at Disease Progression, Peripheral Blood-Based Studies; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: Thalidomide; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cystic Fibrosis
Interventions: VX-659/TEZ/IVA, TEZ/IVA, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 28
States / cities: Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 25 more

Conditions: Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Interventions: NovoTTF-200M device, Best Standard of Care; Device · Other
Lead sponsor: NovoCure GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 61
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 48 more

Conditions: Albinism, Inborn Errors of Metabolism, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Pulmonary Fibrosis
Interventions: Pirfenidone, Placebo; Drug
Lead sponsor: William Gahl, M.D.; NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stage IV Lung Cancer
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1998
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Asthma
Interventions: electronic medication monitoring system, parent-adolescent communication and problem-solving skills; Device · Behavioral
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 9 Years to 15 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 2
States / cities: Kansas City, Missouri • Morgantown, West Virginia

Conditions: Stroke, Stroke, Chronic, Fatigue
Interventions: High frequency repetitive transcranial magnetic stimulation, Sham repetitive transcranial magnetic stimulation; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 34 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Decatur, Georgia • Charleston, South Carolina

Conditions: Asthma, Allergy
Interventions: Broccoli Sprouts, Alfalfa Sprouts; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lung Cancer
Interventions: Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Bortezomib 1.8 mg/m2, Carboplatin AUC 6, Bevacizumab, Taxotere; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Cystic Fibrosis (CF), Cystic Fibrosis - Complete
Interventions: OnTrackCF; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts

Conditions: SARS-CoV 2, COVID, ARDS, ALI, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Dyspnea
Interventions: ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo; Drug · Device
Lead sponsor: APR Applied Pharma Research s.a.; Other
Eligibility: 18 Years to 85 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 13
States / cities: Fullerton, California • Irvine, California • Miami, Florida + 10 more

Conditions: NSCLC Stage IV, NSCLC, Stage IIIC
Interventions: Primary Immune Response (PIR) test by Biodesix, Inc.; Diagnostic Test
Lead sponsor: Addario Lung Cancer Medical Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: San Carlos, California • Chicago, Illinois

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: REGN4659, Cemiplimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Chicago, Illinois • Grand Rapids, Michigan • Charlotte, North Carolina + 3 more

Conditions: COVID-19
Interventions: Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™, Placebo; Drug
Lead sponsor: Jose David Suarez, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Atelectasis
Interventions: Incentive Spirometry, EzPAP® Positive Airway Pressure; Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 79 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hypertension, Pulmonary
Interventions: sildenafil, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 24
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more

Conditions: Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Jacksonville, Florida • Weston, Florida

Conditions: Lung Cancer, Brain Cancer, Head and Neck Cancer
Interventions: Siemens Somatom Definition Edge, Philips Brilliance Big Bore CT/simulator; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Respiratory Distress Syndrome, Covid19
Interventions: T regulatory cells; Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biospecimen Collection, Immune Checkpoint Inhibitor; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pulmonary Arterial Hypertension
Interventions: Dose A KER-012, Dose B KER-012, Dose C KER-012, Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks; Biological
Lead sponsor: Keros Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 16
States / cities: Scottsdale, Arizona • Tucson, Arizona • Stanford, California + 12 more

Search by objective public record fields.

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies

Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide

A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

Parent-Youth Teamwork in Pediatric Asthma Management

Repetitive Transcranial Magnetic Stimulation, a Form of Non-invasive Brain Stimulation, as a Possible Treatment for Post-stroke Fatigue

Dietary Interventions in Asthma Treatment: Sprouts Study

Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy

OnTrackCF: Engagement, Feasibility, and Acceptability Study

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

LACTYFERRIN™ Forte and ZINC Defense™ and Standard of Care (SOC) vs SOC in the Treatment of Non-hospitalized Patients With COVID-19

Comparing the Effectiveness of Lung Expansion Therapy in Adult Human Subjects

A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension

Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of Patients Treated With Proton or Photon Therapy

Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).